Programs

Clinical & Commercial Programs

AIVITA’s lead therapeutic focus is a patient-specific immunotherapy for the treatment of advanced cancers, currently being investigated in glioblastoma and melanoma. We are also developing a multi-pathogen personalized vaccine kit for the prevention of infectious diseases.

Cancer

Patient-specific dendritic cell, tumor cell immunotherapy for the treatment of glioblastoma and melanoma.

The Clean Super Vaccine

Patient-specific dendritic cell vaccine for the prevention of infectious diseases.

 

  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Commercialization

Tumor-initiating cell vaccine (Glioblastoma)

Glioblastoma (USA)

Tumor-initiating cell vaccine (Melanoma)

Melanoma (USA)

Tumor-initiating cell vaccine + checkpoint inhibitor (Melanoma)

Melanoma (USA)

Tumor-initiating cell vaccine + checkpoint inhibitor (Melanoma)

Melanoma (Japan)

The Clean Super Vaccine

Multi-Pathogen Vaccine